| Literature DB >> 24633341 |
Liu-Sheng Peng1, Yuan Zhuang1, Wen-Hua Li1, Yuan-Yuan Zhou2, Ting-Ting Wang1, Na Chen1, Ping Cheng1, Bo-Sheng Li1, Hong Guo2, Shi-Ming Yang2, Wei-San Chen3, Quan-Ming Zou1.
Abstract
BACKGROUND: Interleukin-32 (IL-32) is a recently discovered proinflammatory cytokine involved in inflammatory diseases. We investigated the expression of IL-32 and its regulation mechanism in the inflammatory response of patients with Helicobacter pylori (H. pylori) infection. DESIGN AND METHODS: IL-32 mRNA and protein expression in gastric tissues was detected by quantitative real-time PCR and immunohistochemistry. The regulation of IL-32 in human gastric epithelia cell line AGS was investigated by different cytokine stimulation and different H. pylori strain infection.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24633341 PMCID: PMC3954549 DOI: 10.1371/journal.pone.0088270
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Gastric IL-32 mRNA in patients with H. pylori infection correlated with inflammation and inflammatory cytokine gene expression.
A. IL-32 mRNA expression was detected by real-time PCR in gastric mucosa tissues from 54 H. pylori-positive patients and 47 H. pylori-negative healthy individuals; B. Analysis of the relationship between IL-32 mRNA levels and the degree of gastric inflammation in H. pylori-positive patients; C. IL-32 mRNA showed a positively correlation with those of TNF-α and IL-1β. *P<0.05; ***P<0.001.
Figure 2IL-32 protein was detected in the gastric biopsy tissues.
A. control isotype IgG (200×); B. A representative microphotograph showing biopsy sections from H. pylori-negative normal controls stained for IL-32 (200×); C. A representative microphotograph showing IL-32 immunostaining in biopsy sections from H. pylori-positive patients (200×) ; D. The immunohistochemistry of IL-32 in the gastric biopsy tissues was semi-quantitatively graded as scores (0 = no expression; 1 = low expression; 2 = intermediate expression; 3 = high expression). *P<0.05; **P<0.01.
Figure 3Induction and regulation of IL-32 mRNA in AGS cells.
A. IL-32 mRNA expression was analyzed in AGS cells after stimulation with TNF-α and/or IL-1β for 24 hours. *P<0.05; B. IL-32 protein expression was detected by Western blot from (A); C. AGS cells were pretreated with 10 µM NF-κB inhibitor (BAY 11-7082), MEK1/2 inhibitor (U0126), p38/MAPK inhibitor (SB203580), JNK inhibitor (SP600125), JAK inhibitor I or the vehicle DMSO for 1 hour prior to IL-1β or TNF-α stimulation. IL-32 mRNA level was determined by real-time PCR. *P<0.05 versus the vehicle DMSO treated cells; D. The level of IL-32 protein was detected after AGS cells pretreation with 10 µM NF-κB inhibitor (BAY 11-7082) or not and then stimulation with TNF-α or IL-1β; E. AGS cells were infected by H. pylori at a MOI = 100 for 24 hours and simultaneously treated with neutralizing antibodies to block TNF-α or IL-1β.
Figure 4IL-32 induction in response to H. pylori infection.
A. IL-32 mRNA level were assessed in AGS cells after H. pylori 11637 strain infection for 24 hours at a MOI of 1, 10, 100; B. IL-32 protein level were detected in (A); C. AGS cells were stimulated with either H. pylori 11637 strain or its isogenic CagA-negative mutant strain for 24 hours, and then the mRNA level of IL-32 was analyzed. Data are mean ± SEM of three separate experiments. *P<0.05; ***P<0.001; D. The protein level of IL-32 was detected and one representative blot was shown from (C).